← Trials/Trial dossier/NCT00439166

CompletedPhase 3

Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

Lead sponsor

Hamilton Health Sciences Corporation

Assets

doxycycline / Rifampin

Listed sites

Recruiting sites

Enrollment

100

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 14-26•Study partner/caregiver required

Primary endpoints

•Clinical Dementia Rating scale•Standardized Alzheimer's disease Assessment Scale -cognitive subscale

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00439166

Org study IDPSI 06-47

Timeline

Milestones

Study start2007-02 (month precision)

Study first posted2007-02-23estimated

Primary completion2010-04actual (month precision)

Study completion2010-12actual (month precision)

Last update posted2018-03-19actual

Assets

Drug assets

doxycycline Rifampin

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female

•Age greater than or equal to 50 years

•Diagnosis of probable Alzheimer's disease by NINCDS-ADRDA criteria

•Standardized Mini-Mental State Examination score 14-26 inclusive

•A caregiver who consents to monitor study medications, report on patient function, bring the patient to visits, etc.

•Vision, hearing, language ability sufficient to complete standardized testing in English.

•Patient consents (or legal representative consents for patient)

•Generally stable level of health where patient may be reasonably expected to complete a 1 year trial

Exclusion criteria

•Other neurodegenerative diseases such as Lewy body or Parkinson's

•Cognitive impairment due to: acute trauma, subdural hematoma, hypoxic cerebral damage, B12 deficiency, infections such as AIDS or meningitis, cerebral neoplasia, endocrine deficiencies, mental retardation

•Significant cerebrovascular disease or multi-infarct dementia

•Intra-cranial pathology such as tumour

•Co-existing medical conditions such as epilepsy, major psychiatric conditions, depression (Cornell Depression in Dementia Scale score of 12 or more), significant liver, kidney, lung, metabolic or endocrine diseases

•Clinically significant cardiac disease such as uncontrolled angina or hypertension

•Anti-dementia treatments other than donepezil, galantamine, rivastigmine, memantine

•Enrollment in trials with other investigational drugs

•Antibiotic use more than one month in the last six months

•Allergy to doxycycline or rifampicin

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Other (unclassified)

Global cognition

1 endpoint

Primary/protocol endpoint

Clinical Dementia Rating scale

Time frame:12 months

descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Standardized Alzheimer's disease Assessment Scale -cognitive subscale

Time frame:12 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.